• image
    Original Article| Open Access

    Resistance mechanism to cisplatin in NCI-H460 non-small cell lung cancer cell line: investigating apoptosis, autophagy, and cytogenetic damage

    Érica Ballestreri , Daniel Simon , Ana Paula de Souza , Camila Schultz Grott , Débora Dreher Nabinger , Rafael Rodrigues Dihl , Ivana Grivicich

    Aim: To investigate the effects of cisplatin on the human non-small cell lung carcinoma (NCI-H460) cell line regarding cytotoxicity, genotoxicity, and expression of genes associated with apoptosis (BIRC5) and autophagy (BECN1). Methods: Cell cultures were treated with cisplatin concentrations... Read more

    Cancer Drug Resist 2018;1:72-81. | doi:10.20517/cdr.2017.02
    Published on: 19 Mar 2018  | Viewed:368  | Downloaded:24
    +HTML| PDF
  • image
    Original Article| Open Access

    Reduction of mitomycin C resistance in human bladder cancer T24 cells by knocking-down ras oncogene

    Osama Sharaf Eldin , Abdel-Motaal Fouda , Amany R. Youssef , Peter Hamilton , Perry Maxwell , Kate E. Williamson

    Aim: Mitomycin C (MMC) is a commonly used as intravesical treatment for superficial bladder cancer. However, its role in combination with ras inhibition has not been investigated. The aim of this study was to explore the role of ras in MMC-induced apoptosis in T24 bladder cancer cells and to... Read more

    Cancer Drug Resist 2018;1:59-71. | doi:10.20517/cdr.2017.01
    Published on: 19 Mar 2018  | Viewed:1155  | Downloaded:52
    +HTML| PDF
  • image
    Original Article| Open Access

    Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations

    Anthony Dominijanni , William H. Gmeiner

    Aim: Resistance to fluoropyrimidine drugs (FPs) is a major cause of mortality in colorectal cancer (CRC). We assessed the potency advantage of the polymeric FP F10 relative to 5-fluorouracil (5-FU) in four human CRC cell lines that differ only in TP53 mutational status to determine how p53... Read more

    Cancer Drug Resist 2018;1:48-58. | doi:10.20517/cdr.2018.01
    Published on: 19 Mar 2018  | Viewed:599  | Downloaded:36
    +HTML| PDF
  • image
    Original Article| Open Access

    Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas

    Fatih M. Uckun , Sanjive Qazi

    Aim: CD22ΔE12 as an oncogenic driver lesion in aggressive and drug-resistant B-precursor acute lymphoblastic leukemia (BPL) cells. The purpose of the present study was to identify the CD22ΔE12-specific signature transcriptome in human BPL cells and evaluate the clinical potential of a nanoscale... Read more

    Cancer Drug Resist 2018;1:30-47. | doi:10.20517/cdr.2017.03
    Published on: 19 Mar 2018  | Viewed:912  | Downloaded:19
    +HTML| PDF
  • image
    Review| Open Access

    How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

    Adrian C. Jaramillo , Farah Al Saig , Jacqueline Cloos , Gerrit Jansen , Godefridus J. Peters

    P-glycoprotein (ABCB1), multidrug resistance protein-1 (ABCC1) and breast cancer resistance protein (ABCG2) belong to the ATP-binding cassette (ABC) superfamily of proteins that play an important physiological role in protection of the body from toxic xenobiotics and endogenous metabolites.... Read more

    Cancer Drug Resist 2018;1:6-29. | doi:10.20517/cdr.2018.02
    Published on: 19 Mar 2018  | Viewed:12  | Downloaded:1
    +HTML| PDF
  • image
    Editorial| Open Access

    Cancer drug resistance: a new perspective

    Godefridus J. Peters Cancer Drug Resist 2018;1:1-5. | doi:10.20517/cdr.2018.03
    Published on: 19 Mar 2018  | Viewed:23  | Downloaded:3
    +HTML| PDF

Submit an article to CDR

CDR publishes pharmacological aspects of drug resistance and its reversal, including drug design, drug delivery, drug distribution and cellular drug resistance. Molecular mechanisms of drug resistance also cover the cellular pharmacology of drug resistance such as influx and efflux pumps (including the ABC pumps), receptors and their ligands, cellular signaling pathways, drug activation and degradation (including Phase I and II metabolism), drug sequestration, target modification and DNA repair. Drug classes to be covered include DNA targeted drugs and antihormones as well as antibodies and protein kinase inhibitors. Both clinical and experimental aspects of drug resistance in cancer are included.

Learn more about the journal and author instructions or get started with your submission.



To receive email updates about the journal, please subscribe here.

Quick Links
  • OAE Publishing Inc. (OAE) is an online open-access publisher specializing in the publication of biomedical peer-reviewed journals...

  • Contact us
  • Leave feedback
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.